Jiehui Deng
Overview
Explore the profile of Jiehui Deng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
2879
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan J, Le H, Deng J, Liu Y, Hao Y, Hollenberg M, et al.
Nat Biomed Eng
. 2025 Feb;
PMID: 39979589
High-dimensional multiplexed imaging can reveal the spatial organization of tumour tissues at the molecular level. However, owing to the scale and information complexity of the imaging data, it is challenging...
2.
Tan J, Le H, Deng J, Liu Y, Hao Y, Hollenberg M, et al.
bioRxiv
. 2024 Sep;
PMID: 39282296
The interaction between tumors and their microenvironment is complex and heterogeneous. Recent developments in high-dimensional multiplexed imaging have revealed the spatial organization of tumor tissues at the molecular level. However,...
3.
Wise D, Pachynski R, Denmeade S, Aggarwal R, Deng J, Febles V, et al.
Prostate Cancer Prostatic Dis
. 2024 Feb;
PMID: 38341461
Background: Dickkopf-related protein 1 (DKK1) is a Wingless-related integrate site (Wnt) signaling modulator that is upregulated in prostate cancers (PCa) with low androgen receptor expression. DKN-01, an IgG4 that neutralizes...
4.
Habault J, Schneider J, Ha S, Ruoff R, Pereira L, Puccini J, et al.
Mol Cancer Ther
. 2023 Jul;
22(10):1166-1181.
PMID: 37486978
Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to...
5.
Deng J, Peng D, Fenyo D, Yuan H, Lopez A, Levin D, et al.
bioRxiv
. 2023 May;
PMID: 37131623
Significance: Loss-of-function mutations in the tumor suppressor of lung adenocarcinoma patients and are associated with resistance to current treatments. Our study identified CD38 as a potential therapeutic target that is...
6.
Adorno Febles V, Hao Y, Ahsan A, Wu J, Qian Y, Zhong H, et al.
Prostate
. 2023 Mar;
83(9):840-849.
PMID: 36988342
Background: Evading immune surveillance is a hallmark for the development of multiple cancer types. Whether immune evasion contributes to the pathogenesis of high-grade prostate cancer (HGPCa) remains an area of...
7.
Zhang H, Nabel C, Li D, OConnor R, Crosby C, Chang S, et al.
J Thorac Oncol
. 2023 Mar;
18(7):882-895.
PMID: 36958689
Introduction: In KRAS-mutant NSCLC, co-occurring alterations in LKB1 confer a negative prognosis compared with other mutations such as TP53. LKB1 is a tumor suppressor that coordinates several signaling pathways in...
8.
Guidry K, Vasudevaraja V, Labbe K, Mohamed H, Serrano J, Guidry B, et al.
Clin Cancer Res
. 2022 Jul;
28(17):3824-3835.
PMID: 35802677
Purpose: Lung adenocarcinoma (LUAD) is a clinically heterogeneous disease, which is highlighted by the unpredictable recurrence in low-stage tumors and highly variable responses observed in patients treated with immunotherapies, which...
9.
Huang Q, Li F, Hu H, Fang Z, Gao Z, Xia G, et al.
Sci Adv
. 2022 Feb;
8(5):eabi9533.
PMID: 35119931
Tuberous sclerosis complex subunit 1 () and 2 () are frequently mutated in non-small cell lung cancer (NSCLC), however, their effects on antitumor immunity remained unexplored. A CRISPR screening in...
10.
Chang C, Jen J, Jiang S, Sayad A, Mer A, Brown K, et al.
Cancer Discov
. 2021 Dec;
12(4):1022-1045.
PMID: 34911733
Significance: DTPs are implicated in resistance to anticancer therapies, but their ontogeny and vulnerabilities remain unclear. We find that HER2 TKI-DTPs emerge from stochastically arising primed cells ("pre-DTPs") that engage...